November 2019 newsletter
Flare V3 release features fully validated and accessible FEP calculations and new workflows We are delighted to announce the release of Flare V3 ...
2013 has been an exciting year for Cresset. From product releases to global events, including a recent trip to China. Dr. Robert Scoffin looks back over the year.
This is the question we are asked most often, but to achieve this we need to handle formally charged groups. Dr. Mark Mackey, Cresset’s CSO, describes our approach.
We aim to achieve a good balance between the provision of powerful science and making that science readily accessible and easily understandable. Is this a difficult act to balance?
Profitable reprofiling opportunities are often created by the publication of new biological targets. Blaze makes rapid assessments of which drugs may be active against the new targets.
Cresset’s 2014 user meetings are open to customers and non-customers and will take place as follows:
Submit an abstract for an oral presentation. Further details will be published in the New Year.
Part II of this new book includes Cresset’s XED force field and Spark.